Stock market anomaly | Rongchang Bio (09995.HK) surged nearly 6% in the closing session, its subsidiary RC148 received FDA approval to conduct Phase II clinical trials in the United States.

According to the Securities Times APP, Rongchang Biotech (09995.HK) rose nearly 6% in the afternoon trading session, as of the time of writing, it was up 5.79% to HK$64, with a turnover of HK$4.79 billion.